Artimplant appoints new CEO

Västra Frölunda, Sweden, August 29, 2006. The biomaterials company Artimplant, appoints Hans Rosén to new CEO, effective immediately.

The Board of Directors has appointed Hans Rosén to new CEO, effective immediately. Hans Rosén, born in 1960, has extensive experience from corporate management in the life science sector, most recently as CEO of Vivolux AB, drug development within cancer therapeutics and earlier as CEO of Diffchamb AB, a food diagnostics company formerly listed on the Stockholm Stock Exchange and acquired by Raiso in 2003. He has board positions in Vivolux AB and Ottonova AB. Ingemar Kihlström, Chairman of Artimplant, said; “Hans Rosén brings valuable commercial, technical and management knowledge to Artimplant. He has global experience within sales & marketing from the medical technology area, is an entrepreneurial driven person and has an excellent technical understanding. We are very pleased having him on board.“ Hans Rosén comments; “I find Artimplant to be a very promising company. The first product applications are receiving market acceptance. The unique Artelon® invention has collected more than eight years successful in-vivo clinical data and regulatory clearance for the first product applications. My challenge is to fully explore the market potential and to make Artimplant profitable.”